DDrare: Database of Drug Development for Rare Diseases

Searched query = "Chronic thromboembolic pulmonary hypertension", "CTEPH", "Idiopathic chronic pulmonary thromboembolism"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 11C-ACETATE; 11C-acetate; ACT-064992; ACT-293987; AMBRISENTAN; Acetate; Adempas; Adempas (Riociguat, BAY63-2521); Adempas®; Ambrisentan; Ambrisentan 5 mg; Ammonia; Atorvastatin; BARNASCAN; BAY 63-2521; BAY 63-2521 IR coated tablet 1.0 mg; BAY 63-2521 IR coated tablet 1.5 mg; BAY 63-2521 IR coated tablet 2.0 mg; BAY 63-2521 IR coated tablet 2.5 mg; BAY 63-2521 IR tablet 0.5 mg; BAY 63-2521 IR tablet 1.0 mg; BAY 63-2521 IR tablet 1.5 mg; BAY 63-2521 IR tablet 2.0 mg; BAY 63-2521 IR tablet 2.5 mg; BAY 63-2521 coated tablets 0.5 mg; BAY 63-2521 coated tablets 1 mg; BAY 63-2521 coated tablets 1.5 mg; BAY 63-2521 coated tablets 2 mg; BAY 63-2521 coated tablets 2.5 mg; BAY 63-2521 tablets 0.5 mg; BAY 63-2521 tablets 1 mg; BAY 63-2521 tablets 1.5 mg; BAY 63-2521 tablets 2 mg; BAY 63-2521 tablets 2.5 mg; BAY1237592; BOSENTAN; BPA; Barnascan; Behavioral: respiratory and exercise therapy; Behavioral: respiratory and exercise therapy with supplemental oxygen; Bosentan; Bosentan monohydrate; Cysteine; D-glucose; Diagnostic Test: Endogenous thrombin potential; Diagnostic Test: Light transmission aggregometry; Diagnostic Test: Platelet function analyzer-100; Diagnostic Test: Rotational thromboelastometry; Edoxaban; FLUDEOXYGLUCOSE; Fludeoxyglucose; GSK1325760; Glucose; Imatinib; Imatinib mesilate; Iodine; JNJ-67896062 / ACT-064992; MACITENTAN; Macitentan; Macitentan 10 mg; Macitentan tablets; Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb; Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth; MultiHance; N-acetyl cysteine; NS-304; NS-304 Placebo; OXYGEN; Opsumit; Opsumit®; Oxygen; Oxygen, liquid; PH-combination therapy; PH-monotherapy; Placebo; Procedure: Ballon Pulmonary Angioplasty; Procedure: Balloon Pulmonary Angioplasty (BPA); Procedure: NO gas; Procedure: Pulmonary Endarteriectomy; Procedure: Pulmonary endarterectomy; Procedure: Supplemental oxygen via a mask; Procedure: long term oxygen therapy; RIOCIGUAT; Radiation: Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3); Radiation: Computed tomography lung subtraction iodine mapping; Remodulin; Remodulin (R); Remodulin 10mg/ml 20ml; Remodulin 1mg/ml 20ml; Remodulin 2.5mg/ml 20ml; Remodulin 5mg/ml 20ml; Riociguat; Riociguat (ADEMPAS, BAY63-2521); Riociguat (Adempas, BAY63-2521); Riociguat Oral Tablet; Ro 47-0203; SELEXIPAG; Sauerstoff; Selexipag; TRACLEER; TRACLEER 125MG 56CPR RIV.; TRACLEER*56CPR RIV 125MG; TREPROSTINIL SODIUM; Thrombin; Tracleer; Treprostinil; Treprostinil Sodium; Treprostinil sodium; Uptravi; Volibris; Warfarin; [18F]Fluoro-2-deoxy-2-D-glucose

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04207593 (ClinicalTrials.gov)	April 1, 2019	17/12/2019	The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia	Prospective, Randomized, Controlled Trial of the Effect of Long-term Oxygen Therapy on 6-minute Walking Distance, Clinical Parameters and Hemodynamics in Patients With PAH and CTEPH	Oxygen Deficiency;Pulmonary Arterial Hypertension;CTEPH	Drug: Oxygen	Heidelberg University	NULL	Recruiting	18 Years	N/A	All	40	Phase 2	Germany
2	EUCTR2018-001387-39-DE (EUCTR)	15/03/2019	30/01/2019	The effect of oxygen therapy in patients with pulmonary Hypertension.	A prospective, randomized, controlled trial to assess the effect of long-term oxygen therapy on 6-minute walking distance, clinical parameters and hemodynamics in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) - SOPHA	pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]		Thoraxklinik-Heidelberg gGmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Germany
3	NCT02558582 (ClinicalTrials.gov)	September 2015	14/9/2015	Effect of Exercise Training in Patients With Pulmonary Hypertension	Effect of Exercise Training in Arterial and Chronic Thromboembolic Pulmonary Hypertension in Switzerland and Standardization With European Countries	Hypertension, Pulmonary	Behavioral: respiratory and exercise therapy;Behavioral: respiratory and exercise therapy with supplemental oxygen	University of Zurich	NULL	Recruiting	18 Years	N/A	All	32	N/A	Switzerland
4	JPRN-UMIN000026882	2015/04/01	10/04/2017	Effect of oxygen administration on pulmonary vascular resistance and cardiac index in patients with chronic thromboembolic pulmonary hypertension.	Effect of oxygen administration on pulmonary vascular resistance and cardiac index in patients with chronic thromboembolic pulmonary hypertension. - Effect of oxygen administration on PVR and CI in CTEPH.	chronic thromboembolic pulmonary hypertension.	Oxygen administration	Department of Cardiology, Hospital Organization Okayama Medical Center	NULL	Complete: follow-up continuing	20years-old	Not applicable	Male and Female	100	Not applicable	Japan
5	NCT01884012 (ClinicalTrials.gov)	May 2013	13/5/2013	Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension		Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension	Procedure: long term oxygen therapy	University of Zurich	NULL	Completed	16 Years	85 Years	All	30	Phase 3	Switzerland
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT01748474 (ClinicalTrials.gov)	December 2012	4/10/2012	Effect of Short-term Oxygen During CPET in Pulmonary Hypertension	Effect of Short-term Oxygen Therapy on Cardiopulmonary Exercise Capacity in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension	Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension;Chronic Cardiorespiratory Disease	Procedure: Supplemental oxygen via a mask	University of Zurich	NULL	Completed	20 Years	80 Years	Both	20	Phase 2	Switzerland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04207593
(ClinicalTrials.gov)

April 1, 2019

17/12/2019

The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia

Prospective, Randomized, Controlled Trial of the Effect of Long-term Oxygen Therapy on 6-minute Walking Distance, Clinical Parameters and Hemodynamics in Patients With PAH and CTEPH

Oxygen Deficiency;Pulmonary Arterial Hypertension;CTEPH

Drug: Oxygen

Heidelberg University

NULL

Recruiting

18 Years

N/A

All

Phase 2

Germany

EUCTR2018-001387-39-DE
(EUCTR)

15/03/2019

30/01/2019

The effect of oxygen therapy in patients with pulmonary Hypertension.

A prospective, randomized, controlled trial to assess the effect of long-term oxygen therapy on 6-minute walking distance, clinical parameters and hemodynamics in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) - SOPHA

pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Thoraxklinik-Heidelberg gGmbH

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Germany

NCT02558582
(ClinicalTrials.gov)

September 2015

14/9/2015

Effect of Exercise Training in Patients With Pulmonary Hypertension

Effect of Exercise Training in Arterial and Chronic Thromboembolic Pulmonary Hypertension in Switzerland and Standardization With European Countries

Hypertension, Pulmonary

Behavioral: respiratory and exercise therapy;Behavioral: respiratory and exercise therapy with supplemental oxygen

University of Zurich

NULL

Recruiting

18 Years

N/A

All

N/A

Switzerland

JPRN-UMIN000026882

2015/04/01

10/04/2017

Effect of oxygen administration on pulmonary vascular resistance and cardiac index in patients with chronic thromboembolic pulmonary hypertension.

Effect of oxygen administration on pulmonary vascular resistance and cardiac index in patients with chronic thromboembolic pulmonary hypertension. - Effect of oxygen administration on PVR and CI in CTEPH.

chronic thromboembolic pulmonary hypertension.

Oxygen administration

Department of Cardiology, Hospital Organization Okayama Medical Center

NULL

Complete: follow-up continuing

20years-old

Not applicable

Male and Female

100

Not applicable

Japan

NCT01884012
(ClinicalTrials.gov)

May 2013

13/5/2013

Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension

Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension

Procedure: long term oxygen therapy

University of Zurich

NULL

Completed

16 Years

85 Years

All

Phase 3

Switzerland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01748474
(ClinicalTrials.gov)

December 2012

4/10/2012

Effect of Short-term Oxygen During CPET in Pulmonary Hypertension

Effect of Short-term Oxygen Therapy on Cardiopulmonary Exercise Capacity in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension

Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension;Chronic Cardiorespiratory Disease

Procedure: Supplemental oxygen via a mask

University of Zurich

NULL

Completed

20 Years

80 Years

Both

Phase 2

Switzerland